🔎 Trials Near Me

Inicio › Dermatomiositis › Massachusetts

Ensayos clínicos de Dermatomiositis en Massachusetts

5 estudios sobre Dermatomiositis buscan participantes en Massachusetts.

Ciudades en Massachusetts

Texto oficial del estudio (inglés)

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  • Research Site, Boston
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06455449

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT03816345

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

  • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
ReclutandoFase 2/3
Edades de 6 a 75 · Todos los sexos · Actualizado el 17 sept 2026 · NCT06154252

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

  • Brigham and Women's Hospital, Boston
  • CTC - Brigham & Women's Hospital, Boston
  • CTH - Brigham & Women's Hospital, Boston
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT05895786

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

  • Brigham And Womens Hospital, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 jul 2026 · NCT07115745

De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.